CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
AREN2231 COG Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) Pediatric CIRB
ARET0231 COG A Single Arm Trial of Systemic and Subtenon Chemotherapy for Groups C and D Intraocular Retinoblastoma Pediatric CIRB
ARET0321 COG A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma: A Groupwide Phase III Study Pediatric CIRB
ARET0331 COG Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma: A Phase III Limited Institution Study Pediatric CIRB
ARET0332 COG A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Groupwide Phase III Study Pediatric CIRB
ARET12P1 COG A Multi-institutional Feasibility Study of Intra-Arterial Chemotherapy Given in the Ophthalmic Artery of Children with Retinoblastoma Pediatric CIRB
ARET2121 COG Intravitreal Melphalan for Intraocular Retinoblastoma Pediatric CIRB
ARST0332 COG Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age: A Groupwide Phase III Study Pediatric CIRB
ARST03P1 COG A Pilot Phase II Study for Children with Infantile Fibrosarcoma Pediatric CIRB
ARST0431 COG Intensive Multi-Agent Therapy; Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma: A Groupwide Phase III Study Pediatric CIRB